Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 27, Issue 5, Pages 799-801Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458520912173
Keywords
Multiple sclerosis; cladribine; human milk; breastfeeding; antimetabolite; relative infant dose
Categories
Funding
- Innovation Fund of the Federal Joint Committee
- Bayer Healthcare Pharmaceuticals
- Biogen
- Teva Pharma
- Merck
Ask authors/readers for more resources
This case report suggests the transfer of cladribine in measurable quantities in human milk, with a relative infant dose of 3.06%. Caution should be advised during lactation.
Background: Cladribine is an antimetabolite used for the treatment of relapsing-remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk. Objective: We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose. Methods: Analysis was done using liquid chromatography-mass spectrometry. Results: The relative infant dose calculated in this study was 3.06%. Conclusion: This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available